The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment ; volume:12 ; number:1 ; day:24 ; month:3 ; year:2020 ; pages:1-10 ; date:12.2020
Alzheimer's research & therapy ; 12, Heft 1 (24.3.2020), 1-10, 12.2020
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-020-00592-8
- URN
-
urn:nbn:de:101:1-2020061604131737724603
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
2025-08-14T10:44:14+0200
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Borland, Emma
- Stomrud, Erik
- van Westen, Danielle
- Hansson, Oskar
- Palmqvist, Sebastian
- SpringerLink (Online service)
Ähnliche Objekte (12)
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns
Reporting frequency of radiology findings increases after introducing visual rating scales in the primary care diagnostic work up of subjective and mild cognitive impairment
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns
Reporting frequency of radiology findings increases after introducing visual rating scales in the primary care diagnostic work up of subjective and mild cognitive impairment
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns
Reporting frequency of radiology findings increases after introducing visual rating scales in the primary care diagnostic work up of subjective and mild cognitive impairment
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias